Top Markets
Coin of the day
Response Genetics, Inc Response Genetics, Inc

Response Genetics, Inc

RGDXQ
株式のランク #42156
Response Genetics, Inc., a life sciences company founded in Los Angeles,... Response Genetics, Inc., a life sciences company founded in Los Angeles, California, in 1999 (originally Bio Type, Inc., before its rebranding in August 2000), focuses on creating, advancing, and commercializing pharmacogenomic tests. These diagnostic tools are crucial for informing cancer treatment decisions by assessing specific indicators within tumor tissue samples that predict a patient's response to therapy. The company provides an extensive array of testing services, primarily through its ResponseDX suite, covering various cancers such as non-small cell lung, colorectal, gastric, gastroesophageal, melanoma, thyroid, breast, and glioma, in addition to a Tissue of Origin test. Beyond these existing solutions, Response Genetics is committed to expanding its diagnostic offerings to encompass other tumor types, while also delivering both the technical execution and professional interpretation components of its testing services. Operating globally, with a significant presence in the United States and Europe, Response Genetics serves a wide range of clients including community oncologists, pathologists, medical practices, hospitals, and pharmaceutical enterprises, primarily through its internal sales force.
株価
$0.0001
最終同期: 2026-08-11
時価総額
$3.87K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Response Genetics, Inc (RGDXQ)

カテゴリー

Response Genetics, Inc(RGDXQ)の利益
2026 時点の利益 TTM: 0
Response Genetics, Inc の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Response Genetics, Inc の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益